☆ 4.6 Letter

Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia

AMERICAN JOURNAL OF HEMATOLOGY (2018)

Journal

AMERICAN JOURNAL OF HEMATOLOGY

Volume 93, Issue 4, Pages E88-E91

Publisher

WILEY

DOI: 10.1002/ajh.25020

Keywords

-

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Pharmacology & Pharmacy

Development of New Drugs for Autoimmune Hemolytic Anemia

Zhengrui Xiao, Irina Murakhovskaya

Summary: AIHA is a rare autoimmune disorder characterized by the destruction of red blood cells mediated by autoantibodies, presenting challenges in treatment. Traditional first-line therapies have associated adverse effects and treatment failures, with high rates of relapse. Some patients are refractory to available treatments, leading to the importance of novel therapies.

PHARMACEUTICS (2022)

Add to Collection

Article Immunology

A New Murine Model of Primary Autoimmune Hemolytic Anemia (AIHA)

Flavia Dei Zotti, Annie Qiu, Francesca La Carpia, Chiara Moriconi, Krystalyn E. Hudson

Summary: Autoimmune hemolytic anemia is a severe disease with limited treatment options and challenges in RBC transfusions due to autoantibodies against ubiquitous RBC antigens.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Microbiology

Clostridium haemolyticum Infection: A Cause of Hemolytic Anemia in a Patient with Bone Marrow Necrosis

Anne Sophie Lagneaux, Sandrine Henard, Laure Diancourt, Emmanuelle Stein, Pierre Perez, Pierre Mathieu, Corentine Alauzet, Alain Lozniewski

Summary: Clostridium haemolyticum is a fastidious anaerobe that can cause severe infections in humans, leading to hemolysis and other complications. While rare, infections caused by this organism should be considered in febrile patients with severe hemolytic anemia for prompt diagnosis and treatment.

MICROORGANISMS (2021)

Add to Collection

Review Hematology

How I treat warm autoimmune hemolytic anemia

Wilma Barcellini, Bruno Fattizzo

Summary: Warm autoimmune hemolytic anemia is a disease caused by increased destruction of red blood cells by IgG autoantibodies, with complex pathogenic mechanisms and unpredictable prognosis. Treatment options include steroids, splenectomy, immunosuppressants, and rituximab, but challenges exist in choosing and managing these therapies.

BLOOD (2021)

Add to Collection

Review Hematology

Clinical and epidemiological features of paroxysmal cold hemoglobinuria: a systematic review

Jeremy W. Jacobs, Cristina A. Figueroa Villalba, Garrett S. Booth, Jennifer S. Woo, Laura D. Stephens, Brian D. Adkins

Summary: Paroxysmal cold hemoglobinuria (PCH) is a rare autoimmune hemolytic anemia that is often overlooked and challenging to diagnose due to the complicated testing methods required. A systematic review of reported cases revealed that PCH most commonly occurs in children with a preceding viral infection, and corticosteroid use is frequent but potentially ineffective. The presence of complement and absence of IgG bound to red blood cells is the most common DAT result, although other findings were observed in a third of cases.

BLOOD ADVANCES (2023)

Add to Collection

Review Chemistry, Medicinal

Danazol in Refractory Autoimmune Hemolytic Anemia or Immune Thrombocytopenia: A Case Series Report and Literature Review

Hsu-En Huang, Ko-Ming Lin, Jing-Chi Lin, Yu-Ting Lin, Hsiao-Ru He, Yu-Wei Wang, Shan-Fu Yu, Jia-Feng Chen, Tien-Tsai Cheng

Summary: Danazol therapy is an effective option for patients with refractory AIHA and ITP. In a 6-month observational study, 100% of AIHA patients and 75% of ITP patients achieved treatment response. Responders were able to reduce the dose of glucocorticoids and discontinue immunosuppressants.

PHARMACEUTICALS (2022)

Add to Collection

Article Hematology

Autoimmune Hemolytic Anemia in the Pediatric Age Group: The Egyptian Experience

Amina Abdel-Salam, Sherifa Tarek Bassiouni, Alaa Magdi Goher, Eman Shafik Shafie

Summary: This study retrospectively assessed the frequency, clinical and laboratory characteristics, and treatment outcomes of pediatric AIHA in Egypt. It found that AIHA is rare among children, more prevalent in females, and most patients responded well to high-dose IV steroids.

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Review Medicine, General & Internal

The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia

Alessandro Noto, Ramona Cassin, Veronica Mattiello, Gianluigi Reda

Summary: Autoimmune cytopenias are common complications in chronic lymphocytic leukemia, with traditional chemo-immunotherapy employed for treatment. Ibrutinib has shown rapid and durable responses in treating AIHA arising in CLL, while controversy exists regarding the use of idelalisib in cases of AICs.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Review Pathology

Educational cost-effective intervention to reduce pathologist's peripheral blood smears reviews with non-contributory findings: an academic institution experience

Trang K. Lollie, Robyn Parks, Lissette Bakic, Alyssa Ziman, Sheeja Pullarkat

Summary: Peripheral blood smear review is a valuable diagnostic tool, but innovative hematology analyzers have reduced the need for it. Guidelines and discussions with physicians can reduce non-contributory reviews and optimize resource allocation.

JOURNAL OF CLINICAL PATHOLOGY (2022)

Add to Collection

Article Pathology

Bone marrow fibrosis impact on response to azacitidine in myelodysplastic syndromes

Roya Shahidi, Muhajir Mohamed, Archana Sharma, Jessica Heenan, Julia Gardner, Sam Hitchins

Summary: This study aimed to evaluate the impact of azacitidine treatment on MDS patients with bone marrow fibrosis. The study found that patients with fibrotic marrow had shorter overall survival and event-free survival compared to patients without fibrosis. Bone marrow fibrosis was an independent factor affecting overall survival.

PATHOLOGY (2022)

Add to Collection

Article Pediatrics

Type O blood, the MCHC, and the reticulocyte count impact the early recurrence of primary warm-antibody autoimmune hemolytic anemia in children: A retrospective cohort analysis

Jiacheng Li, Xizhou An, Ximing Xu, Li Xiao, Yang Wang, Yao Zhu, Lan Huang, Kainan Zhang, Xinyuan Yao, Weijia Yi, Jiebin Qin, Jie Yu

Summary: This study aimed to identify risk indicators for early recurrence of primary warm-antibody autoimmune hemolytic anemia (w-AIHA) in children and construct an effective recurrence risk assessment model. The results showed that blood type O, low mean corpuscular hemoglobin concentration (MCHC), and high reticulocyte count (Ret) were risk indicators for early recurrence of pediatric primary w-AIHA.

FRONTIERS IN PEDIATRICS (2022)

Add to Collection

Review Medicine, General & Internal

Autoimmune Hemolytic Anemia as a Complication of Congenital Anemias. A Case Series and Review of the Literature

Irene Motta, Juri Giannotta, Marta Ferraresi, Kordelia Barbullushi, Nicoletta Revelli, Giovanna Graziadei, Wilma Barcellini, Bruno Fattizzo

Summary: Congenital anemias can lead to complications such as AIHA (autoimmune hemolytic anemia), which require prompt diagnosis and treatment. Treatment options include steroids, rituximab, and other medications, with consideration of potential triggers for AIHA in patients.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Review Immunology

Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps

Femke V. M. Mulder, Dorothea Evers, Masja de Haas, Marjan J. Cruijsen, Sophie J. Bernelot Moens, Wilma Barcellini, Bruno Fattizzo, Josephine M. I. Vos

Summary: This article discusses severe autoimmune hemolytic anemia (AIHA), including its definition, understanding of severity and prognosis. Though there are no validated predictors for severe disease course, certain risk factors can aid in identifying severe cases. Certain serological subtypes are associated with lower hemoglobin levels, higher transfusion need and mortality. Currently, there is no evidence-based therapeutic approach, but there are general management strategies and emerging therapeutic options. Further research and development of prediction models and new drugs are needed in the future.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Review Medicine, General & Internal

Infectious Complications in Autoimmune Hemolytic Anemia

Juri Alessandro Giannotta, Bruno Fattizzo, Francesca Cavallaro, Wilma Barcellini

Summary: This review provides an overview of the frequency and types of infectious complications in patients with autoimmune hemolytic anemia (AIHA), as well as the risks associated with various treatments. It also discusses infectious complications in AIHA secondary to other diseases and viral and bacterial reactivations during immune suppressive therapies, along with suggested screening and prophylactic strategies.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Pediatrics

Mycophenolate mofetil for autoimmune cytopenias in children: high rates of response in inborn errors of immunity

Ruben Berrueco, Elisa Gonzalez-Forster, Angela Deya-Martinez, Maria Solsona, Ana Garcia-Garcia, Joan Calzada-Hernandez, Luo Yiyi, Alexandru Vlagea, Anna Ruiz-Llobet, Laia Alsina

Summary: The second-line treatments for autoimmune cytopenias (AC) in children are not well defined. This study found that mycophenolate mofetil (MMF) is a safe and effective immunosuppressant for prolonged AC. The overall response rate of MMF was 73.3%, and all patients with Evans syndrome achieved complete response. Patients with monolineage AC and underlying inborn errors of immunity tended to respond better to MMF.

FRONTIERS IN PEDIATRICS (2023)

Add to Collection

Letter Oncology

Demystifying the diagnostic criteria of indolent systemic mastocytosis

Federica Irene Grifoni, Mariarita Sciume, Giusy Ceparano, Marco Lavezzari, Giulia Galassi, Valerio Pravettoni, Cristina Eller-Vainicher, Simona Muratori, Sonia Fabris, Umberto Gianelli, Diana Giannarelli, Luca Baldini

HEMATOLOGICAL ONCOLOGY (2022)

Add to Collection

Article Surgery

Histological evaluation of ischemic alterations in donors after cardiac death: A useful tool to predict post-transplant renal function

Moreno Zagni, Giorgio Alberto Croci, Antonino Cannavo, Serena Maria Passamonti, Tullia De Feo, Francesca Laura Boggio, Fulvia Milena Cribiu, Marco Maggioni, Stefano Ferrero, Alessandro Del Gobbo, Umberto Gianelli

Summary: Kidneys retrieved from donors after cardiac death (DCD) pose significant challenges and undergo ischemia-reperfusion injury. The current assessment methods cannot predict post-transplant renal function. This study found that proximal tubule alterations play a crucial role in ischemia-reperfusion damage and are closely correlated with functional recovery of the organ.

CLINICAL TRANSPLANTATION (2022)

Add to Collection

Review Chemistry, Medicinal

Efficacy and Immunomodulating Properties of Eltrombopag in Aplastic Anemia following Autologous Stem Cell Transplant: Case Report and Review of the Literature

Marta Bortolotti, Loredana Pettine, Anna Zaninoni, Giorgio Alberto Croci, Wilma Barcellini, Bruno Fattizzo

Summary: Thrombopoietin receptor agonists (TPO-RA) are used to treat chronic immune thrombocytopenia and relapsed refractory aplastic anemia. However, their off-label use is becoming more common, especially in cases of aplasia after chemotherapy and stem cell transplant. Recent evidence suggests that TPO-RA have immunomodulating properties in addition to stimulating platelet production. In this case study, eltrombopag was effective in treating prolonged bone marrow aplasia caused by autologous stem cell transplant. The drug also had an effect on inflammatory cytokine levels and bone marrow histology. This review of literature highlights the efficacy and safety of TPO-RA after stem cell transplant and chemotherapy for hematologic conditions.

PHARMACEUTICALS (2022)

Add to Collection

Review Chemistry, Medicinal

Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors

Bruno Fattizzo, Nicolo Rampi, Wilma Barcellini

Summary: Checkpoint inhibitors (CPI) are a novel therapeutic strategy that can effectively target both solid and hematological cancers. However, they can also cause immune-related adverse events (IRAEs) in various organs. Early diagnosis and intervention for these events are crucial.

PHARMACEUTICALS (2022)

Add to Collection

Review Hematology

The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms

Jurgen Thiele, Hans Michael Kvasnicka, Attilio Orazi, Umberto Gianelli, Naseema Gangat, Alessandro M. Vannucchi, Tiziano Barbui, Daniel A. Arber, Ayalew Tefferi

Summary: A group of international experts met to update the World Health Organization classification system for hematopoietic tumors and introduced the new International Consensus Classification (ICC) for Myeloid Neoplasms and Acute Leukemias. The focus of this review is on the ICC-2022 category of JAK2 mutation-prevalent myeloproliferative neoplasms (MPNs) and the importance of bone marrow morphology and genetic markers in disease classification and diagnostics.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Editorial Material Medicine, General & Internal

Diagnosis and Management of Autoimmune Hemolytic Anemias

Wilma Barcellini, Bruno Fattizzo

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Meeting Abstract Hematology

Evaluation of Red Blood Cell Metabolism in Patients with Low-Risk Myelodysplastic Syndrome (LR-MDS): A Proof-ofConcept Study

Bruno Fattizzo, Cristina Vercellati, Anna Marcello, Marta Bortolotti, Anna Zaninoni, Elisa Fermo, Paola Bianchi, Wilma Barcellini

BLOOD (2022)

Add to Collection

Review Pathology

Fibroblastic/cytokeratin-positive interstitial reticular cell tumor of the spleen with indolent behavior: a case report with review of the literature

Carlo Pescia, Gianluca Lopez, Umberto Gianelli, Giorgio Alberto Croci

Summary: Fibroblastic reticulum cell tumor (FRCT) is a rare dendritic neoplasm that usually occurs in lymph nodes but can also be found in the spleen and soft tissues. These tumors exhibit peculiar cytokeratin expression. The clinical presentation can range from very slow-growing to aggressive disease with features of malignancy. FRCT is challenging to diagnose due to its rarity and deceptive cytokeratin expression.

VIRCHOWS ARCHIV (2023)

Add to Collection

Article Immunology

Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan

Bruno Fattizzo, Francesco Versino, Anna Zaninoni, Anna Paola Maria Luisa Marcello, Cristina Vercellati, Silvia Artuso, Wilma Barcellini

Summary: This study reported the first Italian patient treated with pegcetacoplan in a named patient program for paroxysmal nocturnal hemoglobinuria (PNH). Treatment with pegcetacoplan resulted in significant improvement in the patient's condition, with good tolerability, providing a safe and effective option for PNH patients with suboptimal response to anti-C5 agents.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Evaluation of the main regulators of systemic iron homeostasis in pyruvate kinase deficiency

Anna Zaninoni, Roberta Marra, Elisa Fermo, Dario Consonni, Immacolata Andolfo, Anna Paola Marcello, Barbara Eleni Rosato, Cristina Vercellati, Wilma Barcellini, Achille Iolascon, Paola Bianchi, Roberta Russo

Summary: This study investigated iron homeostasis and dyserythropoiesis in pyruvate kinase deficiency (PKD) patients. The results showed that PKD patients had intermediate levels of sTfR, hepcidin, ERFE, and EPO between CDAII and HS. PKD patients also exhibited higher levels of sTfR and similar levels of EPO compared to CDAII, but both higher than in HS.

SCIENTIFIC REPORTS (2023)

Add to Collection

Letter Hematology

Immunomodulatory cytokines and clonal dynamics in low-risk myelodysplastic syndromes patients treated with luspatercept

Bruno Fattizzo, Alfredo Marchetti, Anna Zaninoni, Marta Lionetti, Marta Riva, Lorenzo Rizzo, Loredana Pettine, Nicole Galli, Federico Mazzon, Elisa Fermo, Akihiro Maeda, Alessio Marella, Matteo Claudio Da Via, Francesco Passamonti, Niccolo Bolli, Wilma Barcellini

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Review Cell Biology

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases

Leonie Saft, Hans M. Kvasnicka, Ludmila Boudova, Umberto Gianelli, Stefano Lazzi, Maria Rozman

Summary: Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions are rare hematopoietic tumors with diverse clinical and morphological presentations. Diagnosis of specific TK gene fusions may require additional evaluation with advanced molecular genetic techniques. The addition of new entities and genetic alterations involving TK genes in the latest classifications highlights the importance of studying M/LN-eo with TK gene fusions.

HISTOPATHOLOGY (2023)

Add to Collection

Editorial Material Chemistry, Medicinal

Drug Design and Development for Rare Hematologic Diseases

Bruno Fattizzo, Marco Capecchi, Irene Motta

PHARMACEUTICALS (2023)

Add to Collection

Meeting Abstract Medicine, Research & Experimental

Paratesticular Extramedullary Hematopoiesis in Children

Elisabetta Kuhn, Letterio Runza, Umberto Gianelli

LABORATORY INVESTIGATION (2022)

Add to Collection

Meeting Abstract Pathology

Paratesticular Extramedullary Hematopoiesis in Children

Elisabetta Kuhn, Letterio Runza, Umberto Gianelli

MODERN PATHOLOGY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.